Halberd Corp Stock Price, News & Analysis

Halberd Corporation (OTC PINK: HALB) reported a productive first quarter of 2023, achieving significant milestones in its research and development efforts. Notably, Halberd successfully eradicated antibiotic-resistant bacteria and fungi using its patented laser technology, as confirmed by the CDC. The company has received additional samples from the CDC for further testing. Additionally, Halberd filed Form 15 with the SEC, removing the YIELD designation from its stock symbol. The company secured a contract with Mississippi State University for preclinical testing of a nasal spray to treat Traumatic Brain Injury (TBI), with 75% of the costs prepaid. Halberd continues to pursue government contracts and partnerships with pharmaceutical companies for FDA approval funding, while maintaining a strategic focus on non-dilutive funding opportunities.

Halberd Corporation (OTC PINK:HALB) recently featured President & CEO William A. Hartman, Chief Technical Officer Dr. Mitchell S. Felder, and YSU Professor Dr. Wm. Gregg Sturrus in an interview on 'The Street Reports.' They discussed significant strides in research aimed at eradicating antibiotic-resistant bacteria and harmful fungi supplied by the CDC.

The laser eradication technique, led by Dr. Sturrus, has successfully neutralized various pathogenic strains. Dr. Felder emphasized that no tested pathogens have developed resistance to this extracorporeal method. Additionally, Halberd has initiated pre-clinical testing for a nasal spray designed to mitigate head trauma effects. Hartman expressed optimism about advancing this research into viable therapeutic solutions for chronic diseases and injuries.

Halberd Corporation (OTC PINK:HALB) is collaborating with Youngstown State University (YSU) on innovative research targeting antibiotic-resistant bacteria and Candida auris. This research was highlighted in a recent CBS news segment. Under the guidance of Dr. Cooper, researchers are utilizing laser exposure to effectively kill 90-95% of harmful bacteria in under 10 minutes while preserving beneficial strains. The CDC has shown interest by providing additional strains for testing Halberd's patented laser eradication technique. This new extracorporeal method aims to treat diseases by cleansing infected bodily fluids outside the body, minimizing reliance on antibiotics. Halberd's developments reflect its commitment to advancing disease treatment methodologies and enhancing shareholder value.

Halberd Corporation (OTC PINK:HALB) has initiated preclinical testing of a novel nasal spray aimed at mitigating the adverse effects of Traumatic Brain Injury (TBI) at Mississippi State University (MSU). This study marks a significant milestone as it aims to measure the relationship between head impact severity and brain injury, a first in this field. The nasal spray is designed to inhibit the production of inflammatory cytokines and neurotransmitters following head trauma, potentially improving outcomes when administered shortly after injury. Funded entirely by Epidemiologic Solutions Corporation, the project has 75% of its costs covered and is structured to comply with FDA regulations, paving the way for market approval. The product targets a substantial market gap, with no other treatments addressing TBI prevention in this manner.

Halberd Corporation (OTC PINK:HALB) reported a successful meeting with the CDC on March 29, 2023, highlighting its achievement in eradicating antibiotic-resistant strains of E. coli and Candida auris. The meeting detailed successful testing conducted at Youngstown State University by Drs. Chester Cooper and W. Gregg Sturrus. The CDC representatives expressed interest in future collaborations and committed to providing more dangerous bacterial and fungal strains for testing. Halberd plans follow-up meetings to expedite development and explore funding opportunities for its patented technologies.

Halberd Corporation has entered an agreement with Mississippi State University to conduct pre-clinical testing of its patent-pending nasal spray aimed at mitigating the effects of Traumatic Brain Injury (TBI). The testing will start on April 10, 2023, and concludes by October 10, 2023. Dr. Russell Carr will oversee the research. Halberd's spray is intended to block the over-production of inflammatory proteins following head trauma, potentially benefiting military personnel and athletes. This initiative underscores Halberd's commitment to addressing neurological complications associated with TBI.

Halberd Corporation (OTC PINK:HALB) announced that it has successfully eradicated all antibiotic-resistant E. coli strains supplied by the CDC ahead of a meeting scheduled for March 29, 2023. Utilizing its patented extracorporeal method combined with metallic nanoparticles, over 90% of the bacteria was eliminated in less than 10 minutes. The company is also testing Klebsiella pneumoniae strains and expects results prior to the CDC meeting. Experts praised the rapid pathogen elimination capabilities, noting minimal adverse effects due to the process being outside the body. Halberd's innovative technology aims to advance therapeutic applications.

Halberd Corporation (OTC PINK:HALB) announced its successful eradication of over 90% of antibiotic-resistant E. coli and Candida auris in under 10 minutes using its patented extracorporeal laser eradication process. With a meeting scheduled with CDC representatives on March 29, 2023, Halberd is set to present these breakthroughs. The technology has already shown success with 12 of the 18 E. coli strains and 4 of the 20 Candida auris strains from the CDC. The company aims to further develop this technology and engage with government agencies and potential partners.

Halberd Corporation (OTC PINK:HALB) has achieved a significant milestone by eradicating 99.5% of antibiotic-resistant E. coli in vitro within 10 minutes using a patented laser method combined with metallic nanoparticles. This breakthrough, demonstrated with strains provided by the CDC, may revolutionize healthcare by enabling faster treatments and reducing hospitalizations without antibiotics. The ongoing research aims to continue testing and optimizing the technology for commercial application, with intentions to present findings to government agencies.